Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market

The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Comprehensive Study by CRO Service (Discovery, Preclinical, Clinical Service, Laboratory Service), CMO Service (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging), CRO Research Phase (Phase I, Phase II, Phase III, Phase IV) Players and Region - Global Market Outlook to 2027

The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The pharmaceutical contract development and manufacturing organization (CDMO) involves drug development and manufacturing services on a contract basis with the pharmaceutical companies. The CDMO services comprise active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging, discovery, preclinical, clinical service, laboratory services. The CDMOs includes all type of operations and services involved in drug development and manufacturing, along with marketing.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledCatalent, Inc. (United States), Boehringer Ingelheim Group (Germany), Recipharm AB (Sweden), Pfizer Inc (United States), Lonza Group (Switzerland), Evonik Industries AG (Germany), Syneos Health (United States), Jubilant Life Sciences Ltd. (India), Baxter Biopharma Solutions (United States), LSK Global Pharma Service Co. Ltd. (South Korea), Novotech Pty Ltd. (Australia), Patheon N.V. (United States), Parexel International (United States), Labcorp Drug Development (United States) and Samsung Biologics (South Korea)


This growth is primarily driven by Growing Demand for Pharmaceutical Products, Drug Development and New Therapies with the Rising Novel Diseases.

Globally, a noticeable market trend is evident Technological Advancement in the Drug Discovery to Enhance Development Process of Pharmaceutical Products Major Players, such as Catalent, Inc. (United States), Boehringer Ingelheim Group (Germany), Recipharm AB (Sweden), Pfizer Inc (United States), Lonza Group (Switzerland), Evonik Industries AG (Germany), Syneos Health (United States), Jubilant Life Sciences Ltd. (India), Baxter Biopharma Solutions (United States), LSK Global Pharma Service Co. Ltd. (South Korea), Novotech Pty Ltd. (Australia), Patheon N.V. (United States), Parexel International (United States), Labcorp Drug Development (United States) and Samsung Biologics (South Korea) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 9th February 2021, Quotient Sciences, the drug development, and manufacturing accelerator announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product, and bioanalysis services to over 200 pharma and biotech customers worldwide.
11th February 2020, Catalent, signed an agreement with Zumutor Biologics Inc., to manufacture Zumutor’s, ZM008, for the treatment of solid tumors. Zumutor is a biologics company that develops novel immune-oncotherapeutics to drive transformational improvements in cancer treatment.

Regulatory Insights:
"In an industry of strong growth, the pharmaceutical market continues to evolve finding new options to bring more FDA-approved drug products to market quickly and cost-effectively. The major outsourcing of the development and manufacturing of drug products by CMO contract companies fills critical gaps and is expected to continue or even accelerate over the next few years. Strategic partnerships between drug companies and contract pharma businesses .often fuel strong growth in the pharmaceutical market. Contract pharma companies must adhere to cGMP standards, i.e. for the sterile facility, manufacturing processes, formulation development, etc. to assure patient safety and drug quality."

The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Dynamics:
AttributesDetails
Growth Drivers
  • Growing Demand for Pharmaceutical Products, Drug Development and New Therapies with the Rising Novel Diseases
Influencing Trends
  • Technological Advancement in the Drug Discovery to Enhance Development Process of Pharmaceutical Products
  • The emerging Small and Large Pharmaceutical Companies Outsourcing Activities
Restraints
  • Regulatory Guidelines and Standards Associated with Pharmaceutical Contract Development and Manufacturing Organization (CDMO)
Gaps & Opportunities
  • Surging Government Investment Support for the Pharmaceutical Contract Development and Manufacturing Organization (CDMO)


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
- Analysis about New Entrants in The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Study Sheds Light on
— The The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By CRO Service
  • Discovery
  • Preclinical
  • Clinical Service
  • Laboratory Service

By CMO Service
  • Active Pharmaceutical Ingredient (API) Manufacturing
  • Finished Dosage Formulation (FDF) Development and Manufacturing
  • Secondary Packaging

By CRO Research Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand for Pharmaceutical Products, Drug Development and New Therapies with the Rising Novel Diseases
    • 3.3. Market Challenges
      • 3.3.1. Growing Complexities Involved in CDMO Market Due to Fewer Manufacturing Infrastructure Setup
    • 3.4. Market Trends
      • 3.4.1. Technological Advancement in the Drug Discovery to Enhance Development Process of Pharmaceutical Products
      • 3.4.2. The emerging Small and Large Pharmaceutical Companies Outsourcing Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service, CMO Service, CRO Research Phase and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) (Value)
      • 5.2.1. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: CRO Service (Value)
        • 5.2.1.1. Discovery
        • 5.2.1.2. Preclinical
        • 5.2.1.3. Clinical Service
        • 5.2.1.4. Laboratory Service
      • 5.2.2. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: CMO Service (Value)
        • 5.2.2.1. Active Pharmaceutical Ingredient (API) Manufacturing
        • 5.2.2.2. Finished Dosage Formulation (FDF) Development and Manufacturing
        • 5.2.2.3. Secondary Packaging
      • 5.2.3. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: CRO Research Phase (Value)
        • 5.2.3.1. Phase I
        • 5.2.3.2. Phase II
        • 5.2.3.3. Phase III
        • 5.2.3.4. Phase IV
      • 5.2.4. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Catalent, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boehringer Ingelheim Group (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Recipharm AB (Sweden)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lonza Group (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Evonik Industries AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Syneos Health (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Jubilant Life Sciences Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Baxter Biopharma Solutions (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. LSK Global Pharma Service Co. Ltd. (South Korea)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novotech Pty Ltd. (Australia)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Patheon N.V. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Parexel International (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Labcorp Drug Development (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Samsung Biologics (South Korea)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Sale, by CRO Service, CMO Service, CRO Research Phase and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) (Value)
      • 7.2.1. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: CRO Service (Value)
        • 7.2.1.1. Discovery
        • 7.2.1.2. Preclinical
        • 7.2.1.3. Clinical Service
        • 7.2.1.4. Laboratory Service
      • 7.2.2. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: CMO Service (Value)
        • 7.2.2.1. Active Pharmaceutical Ingredient (API) Manufacturing
        • 7.2.2.2. Finished Dosage Formulation (FDF) Development and Manufacturing
        • 7.2.2.3. Secondary Packaging
      • 7.2.3. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) by: CRO Research Phase (Value)
        • 7.2.3.1. Phase I
        • 7.2.3.2. Phase II
        • 7.2.3.3. Phase III
        • 7.2.3.4. Phase IV
      • 7.2.4. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CRO Service(USD Million)
  • Table 2. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Discovery , by Region USD Million (2016-2021)
  • Table 3. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Preclinical , by Region USD Million (2016-2021)
  • Table 4. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Clinical Service , by Region USD Million (2016-2021)
  • Table 5. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Laboratory Service , by Region USD Million (2016-2021)
  • Table 6. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CMO Service(USD Million)
  • Table 7. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Active Pharmaceutical Ingredient (API) Manufacturing , by Region USD Million (2016-2021)
  • Table 8. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Finished Dosage Formulation (FDF) Development and Manufacturing , by Region USD Million (2016-2021)
  • Table 9. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Secondary Packaging , by Region USD Million (2016-2021)
  • Table 10. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CRO Research Phase(USD Million)
  • Table 11. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Phase I , by Region USD Million (2016-2021)
  • Table 12. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Phase II , by Region USD Million (2016-2021)
  • Table 13. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Phase III , by Region USD Million (2016-2021)
  • Table 14. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Phase IV , by Region USD Million (2016-2021)
  • Table 15. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2016-2021)
  • Table 16. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 17. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 18. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 19. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 20. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 21. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 22. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 23. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 24. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 25. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 26. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 27. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 28. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2016-2021)
  • Table 29. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 30. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 31. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 32. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 33. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 34. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 35. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 36. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 37. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 38. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 39. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 40. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 41. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 42. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 43. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 44. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 45. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 46. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 47. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 48. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 49. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 53. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2016-2021)
  • Table 54. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 55. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 56. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 57. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 58. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 59. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 60. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 61. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 62. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 63. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 64. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 65. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 66. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 67. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 68. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 69. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 70. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 71. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 72. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 73. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 74. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 75. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2016-2021)
  • Table 76. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 77. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 78. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 79. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 80. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 81. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 82. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 83. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 84. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 85. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2016-2021)
  • Table 86. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 87. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 88. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 89. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 90. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 91. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 92. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 93. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 94. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 95. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2016-2021)
  • Table 96. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2016-2021)
  • Table 97. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2016-2021)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CRO Service(USD Million)
  • Table 114. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Discovery , by Region USD Million (2022-2027)
  • Table 115. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Preclinical , by Region USD Million (2022-2027)
  • Table 116. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Clinical Service , by Region USD Million (2022-2027)
  • Table 117. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Laboratory Service , by Region USD Million (2022-2027)
  • Table 118. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CMO Service(USD Million)
  • Table 119. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Active Pharmaceutical Ingredient (API) Manufacturing , by Region USD Million (2022-2027)
  • Table 120. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Finished Dosage Formulation (FDF) Development and Manufacturing , by Region USD Million (2022-2027)
  • Table 121. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Secondary Packaging , by Region USD Million (2022-2027)
  • Table 122. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CRO Research Phase(USD Million)
  • Table 123. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Phase I , by Region USD Million (2022-2027)
  • Table 124. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Phase II , by Region USD Million (2022-2027)
  • Table 125. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Phase III , by Region USD Million (2022-2027)
  • Table 126. The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Phase IV , by Region USD Million (2022-2027)
  • Table 127. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2022-2027)
  • Table 128. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 129. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 130. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 131. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 132. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 133. Brazil The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 134. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 135. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 136. Argentina The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 137. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 138. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 139. Rest of South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 140. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2022-2027)
  • Table 141. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 142. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 143. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 144. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 145. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 146. China The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 147. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 148. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 149. Japan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 150. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 151. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 152. India The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 153. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 154. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 155. South Korea The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 156. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 157. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 158. Taiwan The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 159. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 160. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 161. Australia The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 162. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 163. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 164. Rest of Asia-Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 165. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2022-2027)
  • Table 166. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 167. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 168. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 169. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 170. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 171. Germany The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 172. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 173. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 174. France The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 175. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 176. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 177. Italy The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 178. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 179. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 180. United Kingdom The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 181. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 182. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 183. Netherlands The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 184. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 185. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 186. Rest of Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 187. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2022-2027)
  • Table 188. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 189. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 190. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 191. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 192. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 193. Middle East The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 194. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 195. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 196. Africa The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 197. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by Country USD Million (2022-2027)
  • Table 198. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 199. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 200. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 201. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 202. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 203. United States The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 204. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 205. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 206. Canada The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 207. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Service USD Million (2022-2027)
  • Table 208. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CMO Service USD Million (2022-2027)
  • Table 209. Mexico The Pharmaceutical Contract Development and Manufacturing Organization (CDMO), by CRO Research Phase USD Million (2022-2027)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CRO Service USD Million (2016-2021)
  • Figure 5. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CMO Service USD Million (2016-2021)
  • Figure 6. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CRO Research Phase USD Million (2016-2021)
  • Figure 7. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 8. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 9. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 10. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 11. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 12. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) share by Players 2021 (%)
  • Figure 13. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) share by Players (Top 3) 2021(%)
  • Figure 14. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Catalent, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Catalent, Inc. (United States) Revenue: by Geography 2021
  • Figure 18. Boehringer Ingelheim Group (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Boehringer Ingelheim Group (Germany) Revenue: by Geography 2021
  • Figure 20. Recipharm AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 21. Recipharm AB (Sweden) Revenue: by Geography 2021
  • Figure 22. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc (United States) Revenue: by Geography 2021
  • Figure 24. Lonza Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Lonza Group (Switzerland) Revenue: by Geography 2021
  • Figure 26. Evonik Industries AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Evonik Industries AG (Germany) Revenue: by Geography 2021
  • Figure 28. Syneos Health (United States) Revenue, Net Income and Gross profit
  • Figure 29. Syneos Health (United States) Revenue: by Geography 2021
  • Figure 30. Jubilant Life Sciences Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 31. Jubilant Life Sciences Ltd. (India) Revenue: by Geography 2021
  • Figure 32. Baxter Biopharma Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 33. Baxter Biopharma Solutions (United States) Revenue: by Geography 2021
  • Figure 34. LSK Global Pharma Service Co. Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 35. LSK Global Pharma Service Co. Ltd. (South Korea) Revenue: by Geography 2021
  • Figure 36. Novotech Pty Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 37. Novotech Pty Ltd. (Australia) Revenue: by Geography 2021
  • Figure 38. Patheon N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Patheon N.V. (United States) Revenue: by Geography 2021
  • Figure 40. Parexel International (United States) Revenue, Net Income and Gross profit
  • Figure 41. Parexel International (United States) Revenue: by Geography 2021
  • Figure 42. Labcorp Drug Development (United States) Revenue, Net Income and Gross profit
  • Figure 43. Labcorp Drug Development (United States) Revenue: by Geography 2021
  • Figure 44. Samsung Biologics (South Korea) Revenue, Net Income and Gross profit
  • Figure 45. Samsung Biologics (South Korea) Revenue: by Geography 2021
  • Figure 46. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CRO Service USD Million (2022-2027)
  • Figure 47. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CMO Service USD Million (2022-2027)
  • Figure 48. Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO): by CRO Research Phase USD Million (2022-2027)
  • Figure 49. South America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 50. Asia Pacific The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 51. Europe The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 52. MEA The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
  • Figure 53. North America The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Catalent, Inc. (United States)
  • Boehringer Ingelheim Group (Germany)
  • Recipharm AB (Sweden)
  • Pfizer Inc (United States)
  • Lonza Group (Switzerland)
  • Evonik Industries AG (Germany)
  • Syneos Health (United States)
  • Jubilant Life Sciences Ltd. (India)
  • Baxter Biopharma Solutions (United States)
  • LSK Global Pharma Service Co. Ltd. (South Korea)
  • Novotech Pty Ltd. (Australia)
  • Patheon N.V. (United States)
  • Parexel International (United States)
  • Labcorp Drug Development (United States)
  • Samsung Biologics (South Korea)
Additional players considered in the study are as follows:
Aenova Group (Germany) , FAMAR S.A. (Greece) , Quotient Sciences (United Kingdom) , Sagimet Biosciences (United States)
Select User Access Type

Key Highlights of Report


Jul 2022 231 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Quantitative research analysis
Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market are Catalent, Inc. (United States), Boehringer Ingelheim Group (Germany), Recipharm AB (Sweden), Pfizer Inc (United States), Lonza Group (Switzerland), Evonik Industries AG (Germany), Syneos Health (United States), Jubilant Life Sciences Ltd. (India), Baxter Biopharma Solutions (United States), LSK Global Pharma Service Co. Ltd. (South Korea), Novotech Pty Ltd. (Australia), Patheon N.V. (United States), Parexel International (United States), Labcorp Drug Development (United States) and Samsung Biologics (South Korea), to name a few.
is dominating the The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market.
"Growing Complexities Involved in CDMO Market Due to Fewer Manufacturing Infrastructure Setup" is seen as one of major challenge by many Industry Players of The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
The The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is expected to see a steady growth rate during projected year 2021 to 2027.

Know More About Global The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Report?

Have a Query? Click Here

Other Related Reports

Roll Compactor Comprehensive Study by Type (• <30Kg/Hour, • 30 – 200Kg/Hour, • >200Kg/Hour), Sales Channel (Online, Offline), End User (Pharmaceutical, Food and Beverage, Chemical, Others) Players an...
$ 3500
VLP Vaccines Comprehensive Study by Virus (Covid-19, Zika, HIV, Adeno-Associated Virus, Hepatitis C), Form (Tablet, Injectables, Capsules, Others), End Use (Hospitals, Specialty Clinics), Vaccine (Li...
$ 3650
Antithyroid Drug Comprehensive Study by Type (Propylthiouracil, Methimazole), Application (Hospital, Specialty Clinics), Distribution Channels (Hospital Dispensary, Retail Pharmacy, Online Pharmacy) ...
$ 3500
Yacon Syrup Comprehensive Study by Type (Conventional, Organic), Application (Household, Commercial), Packaging (Bottle, Can, Pouches, Others), Sales Channel (Online, Offline) Players and Region - Gl...
$ 3500
Nasal Antiseptics Comprehensive Study by Type (Lactoperoxidase, Lactoferrin, Interferons, Povidone- Iodine, Alcohols, Others), Application (Hospitals, Laboratories, Clinics, Others), Sales Channel (O...
$ 3500
Aflibercept Drug Comprehensive Study by Application (Diabetic Macular Edoema (DME), Age-Related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)), Distribution (Hospital Dispensary, ...
$ 3650